Protagonist Therapeutics, Inc (NASDAQ:PTGX) Accelerates Toward Near-Term Regulatory Catalysts; Valuation Implies Elevated Risk
![]() |
Pipeline momentum centers on an impending regulatory decision and a strategic opt-out that concentrate catalysts into the near term; the company’s strong cash position contrasts with WMDST’s assessment that the stock is over-valued. |









